 OncLive | In Breast Cancer, Targeted Agents Boost Hormonal Therapies OncLive The success of everolimus (Afinitor) in combination with exemestane has helped pave the way for such strategies, and agents aimed at various mechanisms of resistance to endocrine therapy are being explored, according to Agustin A. Garcia, MD, MMM, ... |
